AGEN vs. OYST, STRO, PSTX, ADAP, ATHA, MNKD, INVA, OPK, IRWD, and LXRX Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Oyster Point Pharma (OYST), Sutro Biopharma (STRO), Poseida Therapeutics (PSTX), Adaptimmune Therapeutics (ADAP), Athira Pharma (ATHA), MannKind (MNKD), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "medical" sector.
Agenus (NASDAQ:AGEN ) and Oyster Point Pharma (NASDAQ:OYST ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
Agenus presently has a consensus price target of $70.00, indicating a potential upside of 346.14%. Given Agenus' higher probable upside, research analysts plainly believe Agenus is more favorable than Oyster Point Pharma.
Agenus has a net margin of -154.88% compared to Oyster Point Pharma's net margin of -901.99%. Agenus' return on equity of 0.00% beat Oyster Point Pharma's return on equity.
Agenus has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
In the previous week, Agenus had 3 more articles in the media than Oyster Point Pharma. MarketBeat recorded 6 mentions for Agenus and 3 mentions for Oyster Point Pharma. Agenus' average media sentiment score of 0.56 beat Oyster Point Pharma's score of 0.00 indicating that Agenus is being referred to more favorably in the media.
Agenus received 434 more outperform votes than Oyster Point Pharma when rated by MarketBeat users. Likewise, 70.14% of users gave Agenus an outperform vote while only 47.69% of users gave Oyster Point Pharma an outperform vote.
61.5% of Agenus shares are owned by institutional investors. Comparatively, 96.7% of Oyster Point Pharma shares are owned by institutional investors. 4.6% of Agenus shares are owned by insiders. Comparatively, 17.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Oyster Point Pharma has lower revenue, but higher earnings than Agenus. Oyster Point Pharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
Summary Agenus beats Oyster Point Pharma on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
